Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

FRF Jul. 3 at 2:09 PM

$ANVS I did some basic research on $GANX. It has different mechanisms of action. It is still earlier stage. I took a very small position.

3 · Reply

Marypennsylvanialand Jul. 3 at 12:37 PM

$ANVS its important to understand that ANVS holds patents that define how Buntanetap works, and also that they are secure for an extended period of time into the future. I don't know if BIIB violates their patents, but ANVS will have look at potential competitors for such violations. At any rate, what's important is the paradigm shift that is occurring for AD & PD treatments, and that is to shut off upstream Tau production. With that said, ANVS is far ahead of all other competitors, with their 3rd P3 study already well under way. All indications seem they on the right track, and success is imminent.

2 · Reply

FRF Jul. 3 at 12:16 PM

$ANVS Diranersen is injected intrathecally every 24 weeks, since it is antisense oligonucleotides, and inherent difference to Buntanetap oral administration as it is highly lipophilic and easily pass blood-brain barrier. lumbar puncture can be difficult in older patients due to degenerative changes of spine that come with age. Lumbar puncture takes about 15 minutes to be done by doctors or physician assistants with fluoroscopy/ x ray guidance. If Biogen is going to Phase3 with Diranersen, Buntanetab is more superb in drug delivery, reduction of more neurotoxins, therefore more likely to succeed.

1 · Reply

FRF Jul. 3 at 11:34 AM

$ANVS

0 · Reply

NolAsrtormZ Jul. 3 at 6:49 AM

https://stocktwits.com/news-articles/markets/equity/biib-stock-ends-higher-why-this-strategist-picks-biogen-over-other-biotech-peers/cZm7GYQR7jB $ANVS

1 · Reply

FRF Jul. 3 at 6:47 AM

$ANVS @NolAsrtormZ I can not link the article of Diranersen phase2 study. I am assuming they picked biomarker positive patients. They did show biomarker reduction. It is antisense oligonucleotide. It did not meet phase 2 primary end point. They intended to go to phase 3. They are not first to reduce tau, Buntanetap did that before. They may claim first to reduce tau with antisense oligonucleotides. We know antibody therapy work by removing amyloid beta. Purely targeting tau may not change clinical outcomes as we know AD hallmark includes amyloid beta. With buntanetap target reduction of multiple neurotoxins, both amyloid beta and tau as well as more. Maria is correct that AD is results of multiple neurotoxins, and more. I would not change my bet on buntanetap.

1 · Reply

NolAsrtormZ Jul. 3 at 3:18 AM

$ANVS Lets see what kind of move $BIIB gets for their mid-term Alzheimers data in Mid July. 👀👀

1 · Reply

NolAsrtormZ Jul. 2 at 9:13 PM

$ANVS perhaps the price chops until 13fs and earnings??? See what institutions have the guts to swim in the water pre-data release. August 14th🤔🤫🫣

0 · Reply

NolAsrtormZ Jul. 2 at 6:56 PM

$ANVS ohhh, the data run-ups

0 · Reply

NolAsrtormZ Jul. 2 at 6:50 PM

$ANVS ***flashback*** 2021 all the way 2 here Not bad price action for a 4 month hold

0 · Reply

Annovis Bio promotes Cheng Fang to chief scientific officer

Jul 1, 2026, 8:00 AM EDT - 3 days ago

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

2026-05-26T15:07:38.000Z - 5 weeks ago

Annovis Bio regains NYSE listing compliance

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Annovis Bio Regains NYSE Listing Compliance

2026-05-20T12:20:11.000Z - 6 weeks ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90

May 20, 2026, 8:00 AM EDT - 6 weeks ago

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

2026-05-19T20:12:17.000Z - 6 weeks ago

Annovis Bio announces common stock and warrants offering, no amount given

May 19, 2026, 4:06 PM EDT - 6 weeks ago

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 15, 2026, 7:30 AM EDT - 7 weeks ago

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Annovis Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Annovis Bio Slides: Corporate presentation

May 7, 2026, 7:30 AM EDT - 2 months ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 10, 2026, 8:30 AM EDT - 3 months ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Apr 8, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Slides: Corporate presentation

2026-04-02T11:54:03.000Z - 3 months ago

Annovis Bio secures U.S. patent for buntanetap

Apr 2, 2026, 7:30 AM EDT - 3 months ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

Mar 24, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Slides: Corporate presentation

2026-03-19T11:56:46.000Z - 3 months ago

Annovis Bio enters partnership with NeuroRPM

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 3 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

2026-03-16T11:41:50.000Z - 3 months ago

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:35:20.000Z - 3 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Mar 16, 2026, 7:30 AM EDT - 3 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 4 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

2026-02-12T13:21:18.000Z - 5 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Feb 12, 2026, 8:00 AM EST - 5 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

2025-12-18T21:40:13.000Z - 7 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Dec 18, 2025, 4:35 PM EST - 7 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 7 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 7 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 7 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

2025-11-18T14:39:45.000Z - 8 months ago

Annovis announces FDA meeting to discuss PDD program

Nov 18, 2025, 8:00 AM EST - 8 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

2025-11-17T13:10:41.000Z - 8 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Nov 17, 2025, 8:00 AM EST - 8 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

2025-11-12T13:11:18.000Z - 8 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:10:52.000Z - 8 months ago

Annovis Bio sees cash runway to 3Q26

Nov 12, 2025, 8:00 AM EST - 8 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 8 months ago

Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Annovis Bio Quarterly report: Q3 2025

2025-11-06T13:32:03.000Z - 8 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Nov 6, 2025, 8:00 AM EST - 8 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

2025-10-27T12:05:25.000Z - 8 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 9 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

2025-10-10T12:36:07.000Z - 9 months ago

Annovis Bio prices 4M shares at $1.50 in registered direct offering

Oct 10, 2025, 8:31 AM EDT - 9 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

2025-10-09T11:35:21.000Z - 9 months ago

Annovis Bio announces new results from Phase 2/3 AD study of buntanetap

Oct 9, 2025, 7:30 AM EDT - 9 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

2025-09-25T11:35:16.000Z - 10 months ago

Annovis Bio appoints Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 10 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 10 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 10, 2025, 12:00 PM EDT - 10 months ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 11 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 12:00 AM EDT - 11 months ago

Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 11 months ago

Annovis Bio Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update

Jun 19, 2025, 6:30 AM EDT - 1 year ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

FRF Jul. 3 at 2:09 PM

$ANVS I did some basic research on $GANX. It has different mechanisms of action. It is still earlier stage. I took a very small position.

3 · Reply

Marypennsylvanialand Jul. 3 at 12:37 PM

2 · Reply

FRF Jul. 3 at 12:16 PM

1 · Reply

FRF Jul. 3 at 11:34 AM

$ANVS

0 · Reply

NolAsrtormZ Jul. 3 at 6:49 AM

https://stocktwits.com/news-articles/markets/equity/biib-stock-ends-higher-why-this-strategist-picks-biogen-over-other-biotech-peers/cZm7GYQR7jB $ANVS

1 · Reply

FRF Jul. 3 at 6:47 AM

1 · Reply

NolAsrtormZ Jul. 3 at 3:18 AM

$ANVS Lets see what kind of move $BIIB gets for their mid-term Alzheimers data in Mid July. 👀👀

1 · Reply

NolAsrtormZ Jul. 2 at 9:13 PM

$ANVS perhaps the price chops until 13fs and earnings??? See what institutions have the guts to swim in the water pre-data release. August 14th🤔🤫🫣

0 · Reply

NolAsrtormZ Jul. 2 at 6:56 PM

$ANVS ohhh, the data run-ups

0 · Reply

NolAsrtormZ Jul. 2 at 6:50 PM

$ANVS ***flashback*** 2021 all the way 2 here Not bad price action for a 4 month hold

0 · Reply

NolAsrtormZ Jul. 2 at 6:48 PM

$ANVS **Flash back** era 2021 so 4 months in advance price began 2 run. Into a PHASE 1 ALZHEIMERS DATA

1 · Reply

NolAsrtormZ Jul. 2 at 6:37 PM

$ANVS most action happened 5 days before data... So yeah it will probably take some patience 🤣

0 · Reply

NolAsrtormZ Jul. 2 at 6:35 PM

$ANVS so im guessing plenty of time 2 add. Probably 6 months at least

0 · Reply

NolAsrtormZ Jul. 2 at 6:33 PM

$ANVS Judging by the previous release. Looks like no 1 cares about price or Fomo until 1 month b4 data release

0 · Reply

EmotionlessRobot Jul. 2 at 1:42 PM

$ANVS

0 · Reply

DontBanMeAgain Jul. 2 at 1:26 PM

$ANVS I've always believed that if the FDA fostered a therapy to greatly reduce the prevalence of toxoplasma gondii in the populations, along with a general brain detox therapy, aging brain disorders would greatly decrease. A LOT! The correlation between the 1/3rd of humans carrying the toxoplasma gondii parasite in the brain and Alzheimer's is significant.

3 · Reply

Marypennsylvanialand Jul. 2 at 12:24 PM

$ANVS there may be a lot of deep regrets on this ticker some day...either those, like me who invested heavily, or others who might have wished they bought more. Time will tell. But the science says they are on to something big, and a paradigm shift away from previous ways of treating AD & PD.

2 · Reply

LongOrShortToMakeMoney Jul. 2 at 12:01 PM

$ANVS like the pumping regarding phase 3 . Over 2 to start shorting

0 · Reply

FRF Jul. 2 at 11:34 AM

$ANVS All I posted were traceable to papers published. We are waiting the phase3 results to confirm those findings and efficacy, which is highly likely to succeed statistically based on the science we know so far. Merck terminated their phase 2 trial, since science and data are not there to even finish phase 2. To start and continue phase 3 is already a feat that beats a lot of other trials. It is pure common sense and science that drugs produced same effects, reducing neurotoxins, through antibodies or protein production regulation, should have same or similar effects of beneficial effects to P tau 17 screen positive patients.

0 · Reply

NolAsrtormZ Jul. 2 at 6:49 AM

$ANVS Whos gonna pay up???

1 · Reply

NolAsrtormZ Jul. 2 at 6:39 AM

$ANVS Sounds like we could be bought out by $MRK if our phase 3 Alzheimers data is good. Perhaps a bidding war from other pharma. What other companies have phase 3 Alzheimers and Parkinsons going???

2 · Reply

FRF Jul. 2 at 4:37 AM

$ANVS Buntanetap also reduced tau and p-tau in CSF based on isotope labelled studies. Merck still has antibody licensed to reduce p-tau in trial.

0 · Reply

Market Cap	66.87M
Revenue (ttm)	0.00
Net Income (ttm)	-28.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	958,300
Avg Vol	1,116,248
Day's Range	N/A - N/A
Shares Out	34.65M
Stochastic %K	76%
Beta	1.19
Analysts	Strong Sell
Price Target	$11.67